Navigation Links
Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
Date:4/24/2013

rgic asthma" by Kai-Michael Beeh , MD, et al. The article was selected for comment by the JACI Editors ("The Editors' Choice") under the heading "Get the balance right - therapeutic immune modulation in patients with allergic asthma".

Financial Results

Three-month period from January 1 to March 31, 2013

On March 31, 2013, funds available for financing the operations (including cash, cash equivalents, financial assets and trade and other receivables) amounted to CHF 23.58 million. The funds were CHF 5.07 million less than on December 31, 2012 (CHF 28.65 million) primarily due to expenses incurred in ongoing operating activities.

On March 31, 2013, the nominal value of convertible bonds not held by the Company amounted to CHF 13.17 million. Cytos did not buy back any convertible bonds on the market during the first quarter of 2013.

Revenue comprising deferred income from licence fees paid by Novartis of CHF 0.25 million has been recognized in the first quarter 2013, unchanged from the first quarter 2012.

The gross cash burn for operating activities, as calculated on the cash flow statement, was CHF 1.72 million on average per month in the first three months of 2013, compared to CHF 1.04 million on average per month in the first quarter of 2012.

Financial summary (IFRS, consolidated)

(in CHF million) Q1 2013 Q1 2012 Revenue 0,3 0,3 Net operating cost (4,0) (3,0) Operating loss (3,7) (2,8) Net (loss) / income (5,4) 2,5 Net (loss) / income per share (in CHF) (0,24) 0,47 December 31, (in CHF million) March 31, 2013 2012 Cash, cash equivalents, financial assets as well as trade and other receivables 23,6 28,7 Full-time equivalents 22,5 20,9

The detailed Q1 Financial Report 2013 can be downloaded at

http://www.cytos.com/uploads/2013/Cytos_Quarter_1_2013_E.pdf
'/>"/>

SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
2. Cytos Biotechnology Strengthens Management Team
3. Plandai Biotechnology, Inc. Announces Shipment Of First Machinery To South African Production Facility
4. PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs
5. Choose New Jersey and Partners to Promote New Jersey As Global Life Science Hub at Worlds Largest Biotechnology Event
6. Plandai Biotechnology, Inc. Enters Into License Agreement With Phyto Nutricare To Develop Nutraceutical Products
7. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
8. NanoSight, One of the UKs Fastest Growing Biotechnology Companies, Wins a 2013 Queens Award for Enterprise - Innovation
9. Global Biotechnology Industry Market Research Report Now Available from IBISWorld
10. Plandai Biotechnology, Inc. Updates Progress Of Preparing Products For Market
11. San Diego State University Hosts Open House for Life Science Immersion Biotechnology Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Md. , Oct. 1, 2014  Spherix ... to the fostering and monetization of intellectual property, ... litigation against VTech and Uniden in the U.S. ... Texas has been rescheduled for ... for October 2, 2014.  The Court Order setting ...
(Date:10/1/2014)... September 30, 2014 Today the ... round of grants for the Brain Research through ... aims to develop and revolutionize new methods of ... the human brain. This first round of grants ... 2014 was allocated to more than 100 investigators ...
(Date:10/1/2014)... 01, 2014 Slone Partners , ... Healthcare IT, and Laboratory Testing industries, reported a 120% ... the director level and above from July 2013 to ... on top of rapid breakthroughs in diagnostics, reimbursement has ... companies have been forced to fold, consolidate, or carry ...
(Date:10/1/2014)... 2014 Industry leaders from ... engage around the theme, ,Commercial Opportunities in the Era ... Elsevier , a world-leading provider of ... host a gathering of some of the industry,s most ... healthcare today and in the future. The ...
Breaking Biology Technology:Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... Immucor, Inc. (Nasdaq: BLUD ), ... to the blood transfusion industry, announced today that ... Clinical Laboratories, LLC, one of the largest regional ... serving 27 hospitals in Illinois and Indiana. Under ...
... VANCOUVER, May 27 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ... announced that its corporate partner, Boston Scientific Corporation ... from the U.S. Food and Drug Administration (FDA) ... Stent System, a highly deliverable, next-generation drug-eluting stent ...
... DUROS(R) continuous delivery of exenatide for the treatment of ... Inc. today announced it will present clinical data from ... delivery of exenatide) for the treatment of type 2 ... the American Diabetes Association in New Orleans, LA (June ...
Cached Biology Technology:Immucor and Alverno Clinical Laboratories Sign Five-Year Automation Agreement 2Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 2Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 3Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 4Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 5Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions 2Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions 3
(Date:9/30/2014)... German . ... foods in the world. Because they grow underground, people use ... smell of truffles is not only of interest to gourmets. ... of the Goethe University Frankfurt have discovered that the smell ... are trapped inside truffle fruiting bodies. , White truffles from ...
(Date:9/30/2014)... some hope: A new research report published in October ... , explains how scientists developed a synthetic version of ... development in human and mouse eggs similar to the ... during fertilization. , "We believe that the results of ... understanding of human fertilization by providing a precise answer ...
(Date:9/30/2014)... HONG KONG , Sept. 30, 2014 Winners of ... The Economist Events, Innovation Summit scheduled to take place at the ... At the summit, the award winners will share their experiences and ... people who have made a proven innovation over the past decade, ... the night before the summit. It will be the ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... such as temperature, humidity and rainfall will match at ... help to shuffle invasive species, and the diseases they ... The findings provide a framework that could help people ... and cargo aboard --- to plan more efficiently and ...
... Northwest are threatened or endangered, notably salmonids, and hundreds ... their populations and on amelioration efforts. Most of the ... impacts of habitat alteration, hatcheries, harvest, and the hydrosystemthe ... issue of BioScience concludes, however, that nonindigenous ...
... at the University of Southern California (USC) and ... that links increased genetic risk for autism with ... disrupted signaling of the MET gene may contribute ... gastrointestinal dysfunction, says principal investigator Pat Levitt, Ph.D., ...
Cached Biology News:Study predicts when invasive species can travel more readily by air 2Study predicts when invasive species can travel more readily by air 3USC researchers identify gene variant associated with both autism and gastrointestinal dysfunction 2
Request Info...
NATIVE RAT OSTEOCALCIN...
... to Opsin 1 ( Abpromise for all ... peptide: YEDSTHASIFTYT, corresponding to amino acids 14/26 of ... corresponding to amino acids 18/30 of tiger red ... immunogen. Entrez Gene ID: ...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Biology Products: